Document Detail


Integrating innovative therapeutic strategies into the management of renal cell carcinoma.
MedLine Citation:
PMID:  22870536     Owner:  NLM     Status:  In-Process    
Abstract/OtherAbstract:
Three emerging trends have occurred recently in renal cell carcinoma (RCC). First, over the last several decades there has been a marked increase in the diagnosis of RCC, with a corresponding decrease in the typical tumor size, resulting in an increased interest in less invasive approaches to primary tumor treatment. Second, while conventional radiotherapy plays a limited palliative role due to the relative radio-resistance of RCC, advances in immobilization and image guidance have led several investigators to consider stereotactic radiotherapy techniques (SRT) to overcome this resistance, with impressive results in the metastatic setting. In addition, preliminary use of SRT to treat the primary RCC tumor is underway. Thirdly, although RCC is resistant to conventional chemotherapy agents, exciting recent advances have emerged in the treatment of clear cell RCC, with the development of targeted agents in addition to immunotherapy-based treatments. In the current critical review we discuss these emerging trends in localized and systemic treatment as well as possible interesting combinations of the two modalities. Finally, we discuss the role of the new systemic agents in non-clear cell RCC.
Authors:
Janice P Dutcher; Waleed Fouad Mourad; Ronald D Ennis
Related Documents :
22901816 - Juxtarenal wilms tumor in an adolescent.
22465146 - Antitumor and immunomodulatory effects of justicia spicigera schltdl (acanthaceae).
18802696 - Paclitaxel reduces regulatory t cell numbers and inhibitory function and enhances the a...
15846106 - Pwt-458, a novel pegylated-17-hydroxywortmannin, inhibits phosphatidylinositol 3-kinase...
21388336 - Therapeutic targeting of tumor-stroma interactions.
7121806 - Development of a mathematical model of the cervical spinal canal and its use in detecti...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Oncology (Williston Park, N.Y.)     Volume:  26     ISSN:  0890-9091     ISO Abbreviation:  Oncology (Williston Park, N.Y.)     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-08-08     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8712059     Medline TA:  Oncology (Williston Park)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  526-30, 532, 534     Citation Subset:  IM    
Affiliation:
Continuum Cancer Centers of New York, New York, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Comments/Corrections
Comment In:
Oncology (Williston Park). 2012 Jun;26(6):537   [PMID:  22870538 ]
Oncology (Williston Park). 2012 Jun;26(6):534, 536   [PMID:  22870537 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypofractionated radiation therapy for prostate cancer: risks and potential benefits in a fiscally c...
Next Document:  Adjuvant endocrine therapy for breast cancer.